MedImmune, Hopkins In 5-Year Research Pact
BALTIMORE (AP) — Johns Hopkins University and MedImmune say they’re teaming up to find new treatments for complex diseases.
The Daily Record reports that the Baltimore-based university and the Gaithersburg-based company announced their five-year, $6.5 million collaboration Wednesday.
They say the research projects could produce new drugs or therapies for multiple sclerosis, chronic obstructive pulmonary disease and other ailments.
MedImmune and its parent company, AstraZeneca, are committing $5.3 million to the projects. Hopkins will kick in the rest.
A Hopkins medical school official says the research projects will reflect MedImmune’s interests and Hopkins’ expertise.
MedImmune announced a similar, $6 million partnership with the University of Maryland-Baltimore in September.
Information from: The Daily Record of Baltimore, http://www.mddailyrecord.com
(Copyright 2013 by The Associated Press. All Rights Reserved.)